银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02591 银诺医药-B

清明节翌日休市 04-02 16:08:19

20.860

-0.820

-3.78%

最高23.940	最低20.520	成交量89.18万
今开23.940	昨收21.680	日振幅15.77%
总市值95.33亿	流通市值87.67亿	总股本4.57亿
成交额1,950万	换手率0.21%	流通股本4.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"银诺医药-B","latestPrice":20.86,"timestamp":1775117299628,"preClose":21.68,"halted":0,"volume":891800,"delay":0,"changeRate":-0.0378228782287823,"floatShares":420285370,"shares":457000000,"eps":-0.8995586540948529,"marketStatus":"清明节翌日休市","change":-0.82,"latestTime":"04-02 16:08:19","open":23.94,"high":23.94,"low":20.52,"amount":19503896,"amplitude":0.157749,"askPrice":20.94,"askSize":3000,"bidPrice":20.86,"bidSize":6800,"shortable":0,"etf":0,"ttmEps":-0.9416898821980295,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":7,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":21.68,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"volumeRatio":0.8777213495272512,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02591","defaultTab":"news","newsList":[{"id":"2624212503","title":"首个国产长效GLP-1产品成绩单出炉，银诺医药一年亏3.4亿，GLP-1价格战已经打响","url":"https://stock-news.laohu8.com/highlight/detail?id=2624212503","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624212503?lang=zh_cn&edition=full","pubTime":"2026-04-02 19:11","pubTimestamp":1775128291,"startTime":"0","endTime":"0","summary":"可以预见，随着大量仿制药涌入，GLP-1的价格将面临进一步巨大冲击，而GLP-1价格战已经悄然打响。2025年6月，玛仕度肽获NMPA批准用于肥胖或超重成人的慢性体重管理。在国内，目前还没有专门为“减肥”适应症获批上市的口服GLP-1药物。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775118515212957683","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4144","BK4590","GLP","BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624567526","title":"港股异动 | 银诺医药-B(02591)早盘涨超3% 依苏帕格鲁肽α正式纳入“齐鲁保”特定药品清单","url":"https://stock-news.laohu8.com/highlight/detail?id=2624567526","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624567526?lang=zh_cn&edition=full","pubTime":"2026-04-02 09:33","pubTimestamp":1775093582,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，银诺医药-B早盘涨超3%，截至发稿，涨2.94%，报22.22港元，成交额196.6万港元。消息面上，4月1日，据银诺医药官微消息，银诺医药依苏帕格鲁肽α(怡诺轻)正式纳入“齐鲁保”互联网门诊特定药品清单，用于成人2型糖尿病患者治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4585","VXUS","02591","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190139755","title":"异动解读 | 银诺医药-B盘中大涨5.74%，年报亮眼、减重管线进展及核心竞争力突出引价值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=1190139755","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190139755?lang=zh_cn&edition=full","pubTime":"2026-03-24 13:26","pubTimestamp":1774330005,"startTime":"0","endTime":"0","summary":"银诺医药-B（02591）今日盘中股价大幅上涨5.74%，引发市场关注。消息面上，公司此前发布的2025年年报表现亮眼，核心产品依苏帕格鲁肽α上市首年即展现强大商业化能力，毛利率高达89%，且公司财务状况稳健，现金储备充足。更关键的是，其减重适应症国内III期临床已完成全部患者入组，预计明年获批，市场潜力巨大，被视为公司未来业绩的“十倍级”增长引擎。此外，产品具备超长效给药、单靶点比肩双靶点疗效、以及全球唯一的“减脂保肌”临床数据等三大核心竞争力，构建了显著的差异化壁垒。这些积极因素共同强化了市场对公司从生物科技公司向成长型企业转型的预期，推动了投资者信心的提升和股价的走强。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154228635","title":"异动解读 | 银诺医药-B盘中大跌5.79%，年度亏损大幅扩大引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1154228635","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154228635?lang=zh_cn&edition=full","pubTime":"2026-03-24 09:42","pubTimestamp":1774316545,"startTime":"0","endTime":"0","summary":"银诺医药-B(02591)今日盘中股价大跌5.79%，引起了投资者的广泛关注。消息面上，公司于近期发布了截至2025年12月31日止年度的业绩报告。报告显示，公司期内收入约为1.315亿元人民币，但净亏损高达3.41亿元，同比大幅扩大95.4%，每股基本亏损0.79元，且公司宣布不派发股息。这份业绩报告显示公司亏损额显著增加，远超市场预期，这直接打击了投资者信心，导致股价在交易时段承压下行。市场分析认为，亏损的急剧扩大反映了公司当前面临的经营挑战，引发了投资者对其未来盈利能力的担忧。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621575707","title":"银诺医药-B(02591)发布2025年度业绩，净亏损3.41亿元，同比扩大95.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621575707","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621575707?lang=zh_cn&edition=full","pubTime":"2026-03-23 23:10","pubTimestamp":1774278609,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布截至2025年12月31日止年度业绩，集团产生约1.315亿元(人民币，下同)的收入，主要来自于在中国销售依苏帕格鲁肽α。净亏损3.41亿元，同比扩大95.4%;每股基本亏损0.79元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"银诺医药-B(02591)发布2025年度业绩，净亏损3.41亿元，同比扩大95.4%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110146498","title":"银诺医药-B：2025年度收入约1.31509亿元，多适应症布局加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1110146498","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110146498?lang=zh_cn&edition=full","pubTime":"2026-03-23 22:59","pubTimestamp":1774277983,"startTime":"0","endTime":"0","summary":"于2025年度，银诺医药-B收入约1.31509亿元，主要来自在中国内地销售核心产品依薛帕格鲁α，销售成本约0.14452亿元，毛利约1.17057亿元，毛利率约89.0%。同期研发开支约2.05779亿元、行政开支约0.77400亿元、销售及分销开支约1.76645亿元，全年亏损约3.41363亿元。管理层指出，较高的研发及推广投入导致亏损保持在较大规模。依薛帕格鲁α已纳入国家医保药品目录，为后续人群适应症的拓展奠定基础。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621703555","title":"银诺医药-B(02591)：麦宝文获委任为联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2621703555","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621703555?lang=zh_cn&edition=full","pubTime":"2026-03-23 20:07","pubTimestamp":1774267670,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布公告，施雪玲女士已辞任(i)本公司联席公司秘书、(ii)本公司法律程序文件代理人(根据香港法例第622章公司条例第16部在香港代本公司接收法律程序文件和根据香港联合交易所有限公司证券上市规则第19A.13(2)条在香港代本公司接收法律程序文件或通知之法律程序文件代理人，以及(iii)担任根据上市规则第3.05条的本公司授权代表，基于个人职业发展原因，自2026年3月23日起生效。麦宝文女士已获委任为(i)联席公司秘书、(ii)法律程序代理人及(iii)授权代表，自2026年3月23日起生效。杨东妍女士一直担任并将继续担任另一位联席公司秘书。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620201133","title":"港股异动 | 银诺医药-B(02591)盘中跌超5% 预期年度产生亏损约3.414亿元 年内研发开支增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2620201133","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620201133?lang=zh_cn&edition=full","pubTime":"2026-03-20 11:48","pubTimestamp":1773978490,"startTime":"0","endTime":"0","summary":"消息面上，3月18日，银诺医药-B发布公告，尽管用于治疗2型糖尿病的依苏帕格鲁肽α于中国及澳门商业化上市后，集团于2025年度取得收益约人民币1.315亿元，集团预期本年度将取得亏损约人民币3.414亿元，而截至2024年12月31日止年度则取得亏损约人民币1.747亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02591","BK4588","VXUS","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620970235","title":"银诺医药-B(02591)发盈警 预期2025年产生亏损约3.414亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620970235","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620970235?lang=zh_cn&edition=full","pubTime":"2026-03-18 16:37","pubTimestamp":1773823033,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B 公布，尽管用于治疗2型糖尿病的依苏帕格鲁肽α于中国及澳门商业化上市后，集团于2025年度取得收益约人民币1.315亿元，集团预期本年度将取得亏损约人民币3.414亿元，而截至2024年12月31日止年度则取得亏损约人民币1.747亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"银诺医药-B(02591)发盈警 预期2025年产生亏损约3.414亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197852552","title":"银诺医药-B预计全年亏损扩大 研发投入激增1.03亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197852552","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197852552?lang=zh_cn&edition=full","pubTime":"2026-03-18 16:37","pubTimestamp":1773823032,"startTime":"0","endTime":"0","summary":"广州银诺医药集团股份有限公司近日发布盈利预警公告，预计2023财年将录得显著亏损。公司指出，亏损主要源于研发费用的大幅增加，期内研发支出同比激增约1.03亿元人民币，同时销售及分销成本也有所上升。此次研发费用的大幅增长，反映了银诺医药在创新药管线上的持续投入。银诺医药-B的股价表现将在一定程度上取决于其核心产品能否取得突破性进展，以及公司现金储备能否支撑其研发计划至关键节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178999501","title":"银诺医药-B（02591）：预计2025年度亏损扩大至约3.41亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1178999501","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178999501?lang=zh_cn&edition=full","pubTime":"2026-03-18 16:36","pubTimestamp":1773822994,"startTime":"0","endTime":"0","summary":"银诺医药-B3月18日晚间发布盈利预警称，预计2025年度将录得归属于母公司所有者的亏损约3.41亿元，而上年同期亏损约1.75亿元。期内，公司实现收入约1.32亿元，主要来自核心产品依苏帕格鲁肽α在中国及澳门上市后的商业化销售，上年同期收入为零。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620425636","title":"银诺医药-B(02591)拟实施H股全流通计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2620425636","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620425636?lang=zh_cn&edition=full","pubTime":"2026-03-17 18:38","pubTimestamp":1773743905,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布公告，于2026年3月17日，本公司已就建议将公司的全部境内未上市股份转换为本公司H股向中国证监会提交备案申请。于取得所有相关批准及 ╱ 或备案(包括中国证监会的备案通知及联交所的批准)及遵守所有适用法律、规则及法规后，该等境内非上市股份将转换为H股，而本公司将申请批准该等H股于联交所主板上市及买卖。根据本公司的组织章程细则，转换及上市毋须再召开股东会作批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618070909","title":"IPO“黑函”频现 港交所“密交”扩容箭在弦上","url":"https://stock-news.laohu8.com/highlight/detail?id=2618070909","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618070909?lang=zh_cn&edition=full","pubTime":"2026-03-11 21:12","pubTimestamp":1773234772,"startTime":"0","endTime":"0","summary":"如今，为破解这一痛点，港交所正酝酿一场意义深远的上市制度改革。针对递表上市的“黑函”对于拟上市公司而言，在递交上市申请与通过聆讯之间，通常有数月的时间窗口。香港中小上市公司协会主席席春迎对此表示认同。它允许拟上市公司在通过聆讯前，无需公开披露其上市申请文件，从而获得一个宝贵的“静默期”。港交所此次考虑扩大保密申请范围，其底气正来自于自2018年以来一系列上市制度改革的成功，尤其是“科企专线”的积极反馈。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311211842a46162c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311211842a46162c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02591","BK1131","80388","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618393390","title":"银诺医药-B(02591.HK)3月23日举行董事会会议考虑及批准全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2618393390","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618393390?lang=zh_cn&edition=full","pubTime":"2026-03-10 17:07","pubTimestamp":1773133627,"startTime":"0","endTime":"0","summary":"格隆汇3月10日丨银诺医药-B(02591.HK)宣布，董事会会议将于2026年3月23日(星期一)举行，藉以(其中包括)考虑及批准公司及其附属公司截至2025年12月31日止年度之全年业绩及其刊发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260310/32057375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617154781","title":"银诺医药-B03月05日获主力加仓53.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617154781","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617154781?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:16","pubTimestamp":1772698566,"startTime":"0","endTime":"0","summary":"03月05日, 银诺医药-B股价涨2.06%，报收22.74元，成交金额938.7万元，换手率0.10%，振幅6.91%，量比0.89。银诺医药-B今日主力资金净流入53.6万元，连续3日净流入，上一交易日主力净流入179.8万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为57.14%，平均涨幅为2.37%。该股近5个交易日下跌17.37%，主力资金累计净流入346.0万元；近20日主力资金累计净流入1741.8万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305162146a6a5cb16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305162146a6a5cb16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186566011","title":"银诺医药-B（02591）2月股份变动月报：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1186566011","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186566011?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:52","pubTimestamp":1772614332,"startTime":"0","endTime":"0","summary":"广州银诺医药集团股份有限公司于2026年3月4日发布截至2026年2月28日的证券变动月报表。报告显示，公司本月无新增股份发行或回购行为，股本结构保持稳定。公司注册资本合计为人民币456,819,349元，分为420,285,370股于香港联交所上市的H股，以及36,533,979股未上市股份。公司同时确认已符合香港联交所关于最低公众持股量的要求。公司声明将持续遵守香港联交所《上市规则》及相关法律规定。根据公告信息，本次月报由联席公司秘书杨东妍签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616592225","title":"世界肥胖日｜告别\"周抛\"针！银诺医药积极探索\"每月一针\"减重新方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2616592225","media":"银诺医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616592225?lang=zh_cn&edition=full","pubTime":"2026-03-04 09:00","pubTimestamp":1772586022,"startTime":"0","endTime":"0","summary":"银诺医药积极响应，致力于通过科学研究为肥胖管理提供新的可能。公司在研药物依苏帕格鲁肽α的中国减重IIb期研究取得积极结果，验证了\"每2周一次\"给药方案的潜力；同时，在澳大利亚开展的II期多中心研究正在探索\"双周+月制剂\"的更长效给药方案。结果显示，经过18周治疗受试者平均体重较基线下降10%，平均腰围减少8.4cm。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304092335a69fa908&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304092335a69fa908&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614036100","title":"银诺医药-B02月25日主力净流入70.2万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2614036100","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614036100?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:16","pubTimestamp":1772007366,"startTime":"0","endTime":"0","summary":"02月25日, 银诺医药-B股价涨1.76%，报收27.72元，成交金额844.8万元，换手率0.07%，振幅2.86%，量比1.89。银诺医药-B今日主力资金净流入70.2万元，上一交易日主力净流出0万元。该股近5个交易日上涨0.43%，主力资金累计净流入123.0万元；近20日主力资金累计净流出3378.7万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225162235a4c6685c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225162235a4c6685c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610039647","title":"银诺医药-B02月10日主力净流入318.7万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2610039647","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610039647?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:15","pubTimestamp":1770711328,"startTime":"0","endTime":"0","summary":"02月10日, 银诺医药-B股价涨1.69%，报收27.70元，成交金额1446.5万元，换手率0.12%，振幅5.51%，量比0.37。银诺医药-B今日主力资金净流入318.7万元，上一交易日主力净流出90.0万元。该股近5个交易日下跌1.91%，主力资金累计净流入402.2万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出3312.5万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210161707a492a4a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210161707a492a4a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609563048","title":"银诺医药-B(02591)：杨东妍获委任为联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2609563048","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609563048?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:41","pubTimestamp":1770367311,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布公告，金今女士因个人发展原因辞任公司联席公司秘书，自2026年2月6日起生效。杨东妍女士已获委任为联席公司秘书，自2026年2月6日起生效。杨女士将与另一名现任联席公司秘书施雪玲女士共同履行公司秘书职务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innogenpharm.com","stockEarnings":[{"period":"1week","weight":0.0276},{"period":"1month","weight":-0.1423},{"period":"3month","weight":-0.3143},{"period":"6month","weight":-0.4867},{"period":"1year","weight":0.1167},{"period":"ytd","weight":-0.3192}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0464},{"period":"6month","weight":-0.0746},{"period":"1year","weight":0.0825},{"period":"ytd","weight":-0.0201}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"广州银诺医药集团股份有限公司是一家主要从事医药产品的研发及商业化的中国投资控股公司。该公司主要从事商业化原研人源长效胰高血糖素样肽-1（GLP-1）受体激动剂。该公司致力于开发糖尿病和其他代谢性疾病的疗法。该公司的主要产品依苏帕格鲁肽α（商品名：怡诺轻）用于治疗2型糖尿病（T2D）。该公司的主要候选药物管线产品包括YN014、YN401、YN209、YN203和YN202。该公司主要在国内市场经营其业务。","exchange":"SEHK","name":"银诺医药-B","nameEN":"INNOGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供银诺医药-B(02591)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"银诺医药-B,02591,银诺医药-B股票,银诺医药-B股票老虎,银诺医药-B股票老虎国际,银诺医药-B行情,银诺医药-B股票行情,银诺医药-B股价,银诺医药-B股市,银诺医药-B股票价格,银诺医药-B股票交易,银诺医药-B股票购买,银诺医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供银诺医药-B(02591)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}